Anish Burman · Vicaria
directAre API intermediates exported to US or Europe?
Predominantly Europe.
COHANCE / Q1-FY26 / claim-ledger
Audit the questions that mattered.
Cohance Lifesciences · Analyst questions, management answers, and the quality of the response where the ledger is available.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
67%
Numeric claims
4
Consistency
contradicted
Question ledger
What was answered, and how?
Anish Burman · Vicaria
directAre APIs/intermediates subject to US tariffs?
We don't make APIs, we do intermediates and they are right now not part of the tariffs that are being talked about. As far as we are aware, pharma is exempt and right now we are exempt from any tariff discussion.
Anish Burman · Vicaria
directIf tariffs apply, who bears the cost?
Most of our current agreements with the customers are on FOB basis we do not have the liability to pay the tariff when the goods reach the shore of US.
Dal · Jeff
directWhat is BD team strength and future hiring plans?
In North America we have four BDs. These are all experienced CDMO several of them are PhDs that we have hired in the last nine months or so. They are based in East Coast and West Coast. We also have added a resource in Europe as well as one very seasoned executive to the Japanese market.
Dal · Jeff
directDo innovators know payload source when CDMO supplies?
Final decision is fully with the innovator and innovator is fully aware and it's part of the decision making process on selection of the products that we supply.
Dal · Jeff
directWill Cohance explore mAb manufacturing?
Our focus is to grow with customer and invest with customers. We haven't seen much need and desire actually for customer to really partner with us on that space. Right now we're not looking any mAb capabilities to acquire and invest.
Harid Ahmed · Aventas Park
directIs destocking specific to a few products?
The destocking that you referred to is specific to few products. It's related to two large commercial molecules that we are experiencing the destocking right now.
Harid Ahmed · Aventas Park
partialHow does oligo expansion enhance capabilities?
Our starting point of oligo is predominantly research-driven and the important requirement for us is to have cGMP capabilities. We have figured out nucleotides is one modality subsegment they are looking for. This is the first step of our business progression.
Harid Ahmed · Aventas Park
partialHow will NJ Bio expand to commercial scale conjugation?
We have facility available very close to Princeton and NJ Bio which can be converted at a very fast pace to build commercial capability. It's actually a semi-built facility that is already ready in a pharma park.
Shamsawasan · Goldman Sachs
evasiveWhy confidence in FY26 margin guidance despite Q1 miss?
We have reiterated our guidance both for FY26 and more importantly for the FY30 or 2030 $1 billion. If you isolate the destocking, pharma CDMO has grown at around 30%. We should not interpret anything from a quarter to quarter business.
Shamsawasan · Goldman Sachs
deflectedWhat is the organic growth and margin guidance for FY26?
For us the organic and inorganic are two sides of the same coin. It's about capital allocation. I would urge you guys to kind of think about it in the way we look at and not separating it as an organic or inorganic.
Chaksha · White Pine Investments Management
evasiveWhen will one-time expenses stop appearing?
It's very difficult for me to answer a question about when they can disappear. I mean I would be as interested as you that they disappear but that's the current nature of the business.